



## Resistance in Breast Cancer

Guest Editors:

### Dr. Sonia Pernas

1. Department of Medical Oncology, Catalan Institute of Oncology-Hospital Universitari de Bellvitge, L'Hospitalet de Llobregat, Barcelona, Spain  
2. Breast Cancer Group, Institut d'Investigació Biomedica de Bellvitge-IDIBELL, L'Hospitalet de Llobregat, Barcelona, Spain

### Dr. Romualdo Barroso

Oncology Center, Hospital Sírio-Libanês Brasília, Brasília, Brazil

Deadline for manuscript submissions:

**closed (15 December 2022)**


### Message from the Guest Editors

It is our pleasure to invite you to this Special Issue, entitled *Resistance to Breast Cancer*, which aims to summarize well-known mechanisms of resistance to the various therapies currently available, but also to identify and validate novel and clinically significant biomarkers for the early prediction of response/resistance to therapy and the prognosis of breast cancer.

In this Special Issue, original research articles and cutting-edge reviews are welcome. Research areas may include (but are not limited to) the following:

- Biomarkers of endocrine resistance;
- CDK 4/6 inhibitor resistance;
- Breast cancer heterogeneity;
- Mechanisms of resistance to anti-Her2 therapies;
- Mechanisms of resistance to ADCs;
- Mechanisms of immune evasion in triple-negative breast cancer;
  - Biomarkers of response and resistance to immune checkpoint inhibitors in breast cancer;
  - Mechanisms of resistance to PARP inhibitors.





an Open Access Journal by MDPI

## Editor-in-Chief

### Prof. Dr. Samuel C. Mok

Department of Gynecologic  
Oncology and Reproductive  
Medicine, The University of Texas  
MD Anderson Cancer Center,  
Houston, TX 77030, USA

## Message from the Editor-in-Chief

*Cancers* is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

## Author Benefits

**Open Access:** free for readers, with article processing charges (APC) paid by authors or their institutions.

**High Visibility:** indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

**Journal Rank:** JCR - Q1 (Oncology) / CiteScore - Q1 (Oncology)

## Contact Us

---

Cancers Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland

Tel: +41 61 683 77 34  
[www.mdpi.com](http://www.mdpi.com)

[mdpi.com/journal/cancers](http://mdpi.com/journal/cancers)  
[cancers@mdpi.com](mailto:cancers@mdpi.com)  
[X@Cancers\\_MDPI](https://twitter.com/Cancers_MDPI)